Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report

Edyta Ulińska; Katarzyna Mycko; Elżbieta Sałacińska-Łoś; Agata Pastorczak; Alicja Siwicka; Wojciech Młynarski; Michał Matysiak

doi:10.5114/wo.2016.61848

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2016
vol. 20

Send email

Copy url:

abstract:

Original paper

Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report

Edyta Ulińska

,

Katarzyna Mycko

,

Elżbieta Sałacińska-Łoś

,

Agata Pastorczak

,

Alicja Siwicka

,

Wojciech Młynarski

,

Michał Matysiak

Contemp Oncol (Pozn) 2016; 20 (4): 291-296

DOI: https://doi.org/10.5114/wo.2016.61848

Online publish date: 2016/09/05

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Ulińska E, Mycko K, Sałacińska-Łoś E, et al. Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report. Contemporary Oncology/Współczesna Onkologia. 2016;20(4):291-296. doi:10.5114/wo.2016.61848.

APA

Ulińska, E., Mycko, K., Sałacińska-Łoś, E., Pastorczak, A., Siwicka, A.,  & Młynarski, W. et al. (2016). Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report. Contemporary Oncology/Współczesna Onkologia, 20(4), 291-296. https://doi.org/10.5114/wo.2016.61848

Chicago

Ulińska, Edyta, Katarzyna Mycko, Elżbieta Sałacińska-Łoś, Agata Pastorczak, Alicja Siwicka, Wojciech Młynarski,  and Michał Matysiak. 2016. "Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report". Contemporary Oncology/Współczesna Onkologia 20 (4): 291-296. doi:10.5114/wo.2016.61848.

Harvard

Ulińska, E., Mycko, K., Sałacińska-Łoś, E., Pastorczak, A., Siwicka, A., Młynarski, W.,  and Matysiak, M. (2016). Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report. Contemporary Oncology/Współczesna Onkologia, 20(4), pp.291-296. https://doi.org/10.5114/wo.2016.61848

MLA

Ulińska, Edyta et al. "Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report." Contemporary Oncology/Współczesna Onkologia, vol. 20, no. 4, 2016, pp. 291-296. doi:10.5114/wo.2016.61848.

Vancouver

Ulińska E, Mycko K, Sałacińska-Łoś E, Pastorczak A, Siwicka A, Młynarski W et al. Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report. Contemporary Oncology/Współczesna Onkologia. 2016;20(4):291-296. doi:10.5114/wo.2016.61848.

PlumX metrics:

Aim of the study: To characterise expression of mTOR (mammalian target of rapamycin) in childhood B-cell acute lymphoblastic leukaemia (ALL), and to evaluate a possible link between mTOR and clinical characteristics.

Material and methods: The examined group consisted of 21 consecutive patients, aged 1–18 years, diagnosed with B-cell ALL in 2010, and 10 relapsed B-cell ALL patients diagnosed for the first time between 2009 and 2011, who developed relapse before 2014. All subjects were treated in the Department of Paediatric Haematology and Oncology of the Medical University of Warsaw according to the ALL-IC BFM 2002 Protocol. We evaluated mTOR and phospho-mTOR expression by immunohistochemistry using rabbit monoclonal antibodies.

Results: mTOR expression was found to be significantly associated with the risk of relapse and was more frequent in ALL recurrence. No significant relationship was detected between mTOR expression and other features of high-risk disease in paediatric ALL. Conclusions: mTOR activity could be considered a high-risk feature in paediatric B-cell ALL. Expression of mTOR kinase is observed remarkably more frequently in disease recurrence than at first diagnosis, indicating higher proliferative and survival potential of leukaemic cells in relapse. Routine analysis of mTOR activity could be performed to select patients that may potentially benefit from mTOR inhibitors (MTI) treatment.

keywords:

Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report

Edyta Ulińska , Katarzyna Mycko , Elżbieta Sałacińska-Łoś , Agata Pastorczak , Alicja Siwicka , Wojciech Młynarski , Michał Matysiak

ALL, childhood, mTOR protein, relapse, prognosis

Edyta Ulińska

,

Katarzyna Mycko

,

Elżbieta Sałacińska-Łoś

,

Agata Pastorczak

,

Alicja Siwicka

,

Wojciech Młynarski

,

Michał Matysiak